Physician profile
Amina Dafalla
NPI 1497194864
$1,128.77
in general payments reported to CMS, 2019-2025
21 companies · $476 in 2025
The $476 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.84 · 2021: $27.24 · 2023: $90.60 · 2024: $504 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.99 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $151.82 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Biogen, INC. | $148.77 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $130.57 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Sumitomo Pharma America, INC. | $88.24 | 2025 | Myfembree |
| Daiichi Sankyo INC. | $61.18 | 2023-2024 | Injectafer |
| Astellas Pharma US INC | $59.15 | 2024 | Veozah |
| Pfizer INC. | $59.00 | 2023-2025 | |
| Shield Therapeutics INC | $58.50 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $57.29 | 2023-2025 | |
| Novo Nordisk INC | $47.87 | 2024 | Wegovy |
| Organon LLC | $47.36 | 2024 | |
| Exeltis, USA INC. | $35.77 | 2024 | Nuvessa, Tyblume |
| Welch Allyn | $27.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.17 | 2025 | |
| Pharmacosmos Therapeutics INC. | $22.89 | 2025 | Monoferric |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optumhealth Care Solutions, LLC | $21.62 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Coopersurgical, INC. | $20.94 | 2024 | Paragard T 380a |
| Clovis Oncology, INC. | $19.16 | 2019 | |
| Davol INC. | $17.84 | 2024 | Arista Ah Flexitip |
| Abbvie INC. | $15.71 | 2023 | Lo Loestrin Fe, Orilissa |
| Lupin INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amina Dafalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.